The verdict
Our read at a glance.
Whether a compound developed to put weight on beef cattle has any established profile in people.
- The signal
- The pharmacology is not in doubt: 17-beta-trenbolone is a potent androgen receptor agonist, and a 2010 review examined its tissue selectivity and speculated about clinical applications precisely because the potency is real. What does not exist is the human evidence. The indexed literature is dominated by animal science, environmental toxicology - trenbolone is an endocrine-disrupting contaminant in water systems downstream of feedlots - and residue detection in cattle. Human disposition was described once, in 1991. The most relevant recent human work is not a trial at all but a 2024 study examining the association between trenbolone use, psychological distress and aggression among people who use it.
- The unknown
- Essentially everything a medicine would need to establish. No human dose-response, no controlled safety data, no cardiovascular or neuropsychiatric follow-up. The neuropsychiatric signal users describe is consistent enough to be worth taking seriously and has never been characterised properly.
- Our read
- The clearest example on this Watchlist of a compound whose reputation is built entirely on user report. It is potent - that part is true. It is also a veterinary product with no human trial of any kind, and the only recent human research on it is about psychological harm.
The mechanism
How it works.
Trenbolone is a 19-nortestosterone derivative with additional double bonds that make it resistant to metabolism and a very high-affinity androgen receptor agonist - substantially more potent than testosterone at the receptor. It is not a substrate for aromatase, so it produces no oestradiol of its own, which is why its effects on water retention differ from testosterone and why users who run it alone can still suppress oestrogen to symptomatic levels through shutdown of their own testosterone. Like other 19-nor compounds it has progesterone receptor activity. It also binds the glucocorticoid receptor, which is part of the proposed explanation for its effect on fat mass. In cattle this combination produces reliable feed-efficiency and carcass changes, which is what it was designed for.
Safety & regulatory boundary
The consequential part.
Not approved for human use anywhere. A Schedule III controlled substance in the United States. Legally manufactured only as veterinary implants, which means human-market product is either diverted, converted, or made outside any pharmaceutical standard. Strongly suppressive of the gonadal axis, progestogenic like other 19-nor compounds, and with no aromatisation to buffer it. Prohibited in sport at all times.
What's next
What we're watching.
Any characterisation of the neuropsychiatric effects, and any human pharmacokinetic work, which would be the first in over thirty years.
Context
Why this is discussed.
It has the strongest reputation for body-composition change of anything in common use, and that reputation is entirely experiential - there is no trial behind it.
The evidence base
10 cited references.
Indexed literature (PubMed)10
Borecki R et al. · Endokrynol Pol · 2024
Marzin D · Ann Rech Vet · 1991
Mi P et al. · Chemosphere · 2020
Zhang S et al. · Aquat Toxicol · 2023
Piatkowski T et al. · Int J Drug Policy · 2024
Tian H et al. · Sci Total Environ · 2022
Zhang S et al. · Chemosphere · 2022
Pegolo S et al. · Res Vet Sci · 2014
Yarrow JF et al. · Steroids · 2010
Spranger B et al. · J Chromatogr · 1991
Keep reading